top of page

Search

Improvements in body mass index of children with cysticfibrosis following implementation of a stand

Admin
Mar 27, 2023
1 min read

Yasemin Gokdemir MD1 | Ela Erdem Eralp MD1 | Almala Pinar Ergenekon MD1 | Cansu Yilmaz Yegit MD1 | Muruvvet Yanaz MD1 | Hakan Mursaloglu MD2,3 | Burcu Uzunoglu3 | Damla Kocamaz3 | Gamze Tastan3 | Amy Filbrun MD4 | Catherine Enochs BSN4 | Sandra Bouma MS4 | Courtney Iwanicki MS4 | Fazilet Karakoc MD1 | Samya Z. Nasr MD4 | Bulent Karadag MD1

Recent Posts

Annual Scientific Conference

Annual Scientific Conference

The Heartbreaking Reality of Cystic Fibrosis Care in Iraq: A Mother's Plea for Help

Meet Sara from Iraq, a courageous mother fighting an uphill battle to ensure her daughter, Rozhin, receives the care she desperately...

MECFA supports CF patients in Tunisia

Tunisia is home to about 250 people with cystic fibrosis (CF), which was first discovered in 1994. Tunisia's population is approximately...

Commentaires

Featured Posts

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

A case for improved carrier screening

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p

Recent Posts

Annual Scientific Conference

The Heartbreaking Reality of Cystic Fibrosis Care in Iraq: A Mother's Plea for Help

MECFA supports CF patients in Tunisia

International disparities in diagnosis and treatment access for cystic fibrosis

Philip Hopewell Prize for Global Respiratory Health Research

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug

MECFA launches campaign to help people with CF in Gaza and the West Bank, Palestine

Ministry of Health unveils national electronic registry for cystic fibrosis patients

MECFA Jordan Project report

Conquering chronic lung infection in cystic fibrosis patients

Archive

Search By Tags

bottom of page